Search our Database of Scientific Publications and Authors

I’m looking for a

    3649 results match your criteria Alopecia Areata

    1 OF 73

    High dose pulsed corticosteroid therapy combined with Methotrexate for Severe Alopecia Areata of Childhood.
    J Eur Acad Dermatol Venereol 2017 Apr 20. Epub 2017 Apr 20.
    Department of Pediatric Dermatology, National Centre for Rare Skin Disorders, Hôpital Pellegrin-Enfants, CHU de Bordeaux, Bordeaux, France.
    Alopecia areata (AA) in childhood can run a chronic course and worsen over time(1). Spontaneous hair regrowth is rarely appreciated in chronic severe AA(2-4). Our centre described the ineffective use of high dose pulsed corticosteroid therapy (HDPCT) in the long term(1). Read More

    CD80CD86 deficiency disrupts regulatory CD4+FoxP3+T cell homeostasis and induces autoimmune-like alopecia.
    Exp Dermatol 2017 Apr 19. Epub 2017 Apr 19.
    Designed Animal and Transplantation Research Institute, Greenbio Research and Technology, Seoul National University, 1447 Pyeongchang-Ro, Daewha, Pyeongchang, Kangwon, 25354, Korea.
    Alopecia areata (AA) is an autoimmune disease that results in spot baldness in humans. Adequate animal models for AA are currently lacking. The objective of this study was to elucidate the mechanism of autoimmune-like alopecia (ALA) in C57BL/6. Read More

    Oral Lichenoid Reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings.
    J Eur Acad Dermatol Venereol 2017 Apr 17. Epub 2017 Apr 17.
    Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
    Immune checkpoint inhibitors targeting the programmed cell death receptor-1 (PD-1) or its ligand (PD-L1) show broad activity across different tumor types and currently represent one of the keystones of cancer management. Dermatologic toxicities are one of the most frequent immune-related adverse events (irAEs) induced by these new monoclonal antibodies. Maculopapular rash, pruritus, exacerbation of psoriasis or more specific autoimmune disorders (e. Read More

    SOCS3 treatment prevents the development of alopecia areata by inhibiting CD8+ T cell-mediated autoimmune destruction.
    Oncotarget 2017 Mar 23. Epub 2017 Mar 23.
    Department of Plastic and Reconstructive Surgery, Shanghai 9th People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
    Alopecia areata is one of the most common autoimmune diseases resulting from T cell-mediated damage of hair follicles. CD8+ T cells infiltrate hair follicles and are responsible for destruction of hair follicles. However the underlying mechanisms for hair loss remain still obscure. Read More

    The Molecular Revolution in Cutaneous Biology: Emerging Landscape in Genomic Dermatology: New Mechanistic Ideas, Gene Editing, and Therapeutic Breakthroughs.
    J Invest Dermatol 2017 May;137(5):e123-e129
    INSERM UMR 1163, Paris, France; Imagine Institute, Paris, France; University Paris Descartes Sorbonne Cité, Paris, France; Department of Genetics, Necker Hospital for Sick Children, Paris, France. Electronic address:
    Stunning technological advances in genomics have led to spectacular breakthroughs in the understanding of the underlying defects, biological pathways and therapeutic targets of skin diseases leading to new therapeutic interventions. Next-generation sequencing has revolutionized the identification of disease-causing genes and has a profound impact in deciphering gene and protein signatures in rare and frequent skin diseases. Gene addition strategies have shown efficacy in junctional EB and in recessive dystrophic EB (RDEB). Read More

    The Molecular Revolution in Cutaneous Biology: The Era of Genome-Wide Association Studies and Statistical, Big Data, and Computational Topics.
    J Invest Dermatol 2017 May;137(5):e113-e118
    National Heart and Lung Institute, Imperial College, London, UK. Electronic address:
    The investigation of biological systems involving all organs of the body including the skin is in era of big data. This requires heavy-duty computational tools, and novel statistical methods. Microarrays have allowed the interrogation of thousands of common genetic markers in thousands of individuals from the same population (termed genome wide association studies or GWAS) to reveal common variation associated with disease or phenotype. Read More

    A retrospective epidemiological study of skin diseases among pediatric population attending a tertiary dermatology referral center in Northern Greece.
    Clin Cosmet Investig Dermatol 2017 3;10:99-104. Epub 2017 Apr 3.
    First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece.
    Background: The incidence of skin diseases in children is influenced by hereditary, social, and environmental factors. The objective of this study was to determine the incidence of pediatric dermatoses at a University Hospital in Northern Greece.

    Patients And Methods: We reviewed epidemiologic data of 940 patients, aged 0-18 years, who were referred to the outpatient clinic of a University Hospital between January 2013 and December 2015. Read More

    The Contributory Roles of Th17 Lymphocyte and Cytotoxic T Lymphocyte at the Hair Bulge Region as Well as the Hair Bulb Area in the Chronic Alopecia Areata Patients.
    Ann Dermatol 2017 Apr 24;29(2):156-166. Epub 2017 Mar 24.
    Department of Dermatology, Dong-A University College of Medicine, Busan, Korea.
    Background: Alopecia areata (AA) is a T cell-mediated autoimmune disease that targets hair follicles and interrupts hair regrowth. The microenvironment of the effector T cells and their related cytokines may affect immunopathogenesis around the hair bulb/bulge.

    Objective: To determine the contributory roles of the effector T cell subsets and related cytokines to the pathogenesis of AA. Read More

    Review of treatment for alopecia totalis and alopecia universalis.
    Int J Dermatol 2017 Apr 5. Epub 2017 Apr 5.
    Department of Dermatology, University of California Irvine, Irvine, CA, USA.
    Alopecia areata (AA) is an autoimmune disease directed at the hair follicle. Although usually limited to patchy hair loss over the scalp (focalis), AA can present as total loss of scalp hair (totalis; AT) or as total loss of both scalp and body hair (universalis; AU). Management of AT and AU can be challenging, and although multiple treatment modalities have been explored, no therapy is currently FDA-approved. Read More

    Parent-of-origin Effect in Alopecia Areata: A Large-scale Pedigree Study.
    Acta Derm Venereol 2017 Mar 28. Epub 2017 Mar 28.
    Heinrich-Heine-University, Medical Faculty, , Institute of Human Genetics, , 40225 Düsseldorf, Germany.
    is missing (Short communication). Read More

    TNF inhibitor induced alopecia: an unusual form of psoriasiform alopecia that breaks the Renbök mold.
    Dermatol Online J 2017 03 15;23(3). Epub 2017 Mar 15.
    University of Wisconsin, Departments of Internal Medicine and Dermatology, Madison, Wisconsin.
    TNF-α-inhibitors are known to induce skin adverseeffects including psoriasis and alopecia areata. Here, wedescribe a unique pattern of hair loss that has psoriaticand alopecia areata-like features. Diagnosis requiresclinical-pathologic correlation and is supportedby increased catagen/telogen hairs, psoriasiformepidermal hyperplasia, perifollicular lymphocyticinfiltrate, and the presence of eosinophils and plasmacells. Read More

    Can mindfulness-based interventions improve the quality of life of patients with moderate/severe alopecia areata? A prospective pilot study.
    J Am Acad Dermatol 2017 Apr;76(4):757-759
    Section of Dermatology, Department of Health Sciences, University of Genoa, Genoa, Italy; Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Azienda Ospedaliera Universitaria (AOU) San Martino-Istituto Nazionale per La Ricerca sul Cancro (IST) Genoa, Italy.

    Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring.
    Int J Dermatol 2017 Mar 21. Epub 2017 Mar 21.
    Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
    Background: Alopecia areata is a relatively common condition affecting patients seen in community dermatology clinics. A 2014 study implicated the JAK1/JAK2 inhibitor, ruxolitinib in short-term treatment of alopecia, however little information exists about the long-term use in otherwise healthy individuals in the community setting.

    Methods: A patient with chronic alopecia areata and a patient with acute onset alopecia universalis were treated with oral ruxolitinib for over a year. Read More

    Lupus erythematosus tumidus of the scalp masquerading as alopecia areata.
    Cutis 2017 Feb;99(2):E22-E24
    Dermatology Residency Program, San Antonio Uniformed Services Health Education Consortium, Texas, USA.
    Lupus erythematosus tumidus (LET) is a unique subset of chronic cutaneous lupus erythematosus (CCLE) that generally presents as urticarialike papules and plaques with induration and erythema on the face, trunk, and upper extremities. Lesions rarely present on the scalp or below the waist. We report a unique case of LET on the scalp of a woman that presented clinically as alopecia areata. Read More

    Alopecia areata.
    Nat Rev Dis Primers 2017 Mar 16;3:17011. Epub 2017 Mar 16.
    Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
    Alopecia areata is an autoimmune disorder characterized by transient, non-scarring hair loss and preservation of the hair follicle. Hair loss can take many forms ranging from loss in well-defined patches to diffuse or total hair loss, which can affect all hair-bearing sites. Patchy alopecia areata affecting the scalp is the most common type. Read More

    "X" Marks the Spot: An Injection Technique for Alopecia Areata.
    Pediatr Dermatol 2017 Mar;34(2):214-215
    Department of Dermatology, Henry Ford Health System, Detroit, Michigan.
    Children with alopecia areata often have multiple patches of hair loss. When administering intralesional steroid injections, it can be difficult to monitor which areas have already been treated. Additionally, patients and their parents may worry that we did not treat all of the affected areas. Read More

    Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients.
    J Am Acad Dermatol 2017 May 8;76(5):948-957. Epub 2017 Mar 8.
    St John's Institute of Dermatology, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom; Department of Dermatopathology, St John's Institute of Dermatology, NHS Foundation Trust, Guy's and St Thomas' Hospital, London, United Kingdom. Electronic address:
    Background: Anagen effluvium with reversible scalp alopecia is a known side effect of chemotherapy. However, there are an increasing number of reports in the literature documenting permanent alopecia in patients treated with taxanes.

    Objective: We sought to describe the clinicopathologic features in breast cancer patients who underwent treatment with taxanes and adjuvant hormonal chemotherapy. Read More

    Platelet rich plasma for treatment of non-scarring hair loss: systematic review of literature.
    J Dermatolog Treat 2017 Mar 23:1-8. Epub 2017 Mar 23.
    a Center for Research and Training in Skin diseases and Leprosy, Tehran University of Medical Science , Tehran , Iran.
    Background: Although there are many studies showing the role of platelet rich plasma (PRP) in bone grafts, teeth osteosynthesis, and wound healing, there have been little peer reviewed studies about the safety and efficacy of PRP application in the treatment of hair loss.

    Materials And Methods: In this systematic review, we searched Ovid Medline, Scopus and Web of Knowledge till November 2015 for human studies evaluating the efficacy of PRP for the treatment of non-cicatricial alopecia.

    Results: Among 704 articles retrieved in first search, 18 articles matched our inclusion criteria, 14 for androgenic alopecia and four for alopecia areata. Read More

    Double-stranded RNA induces inflammation via the NF-κB pathway and inflammasome activation in the outer root sheath cells of hair follicles.
    Sci Rep 2017 Mar 7;7:44127. Epub 2017 Mar 7.
    Department of Dermatology, School of Medicine, Chungnam National University, Daejeon, Korea.
    Alopecia areata (AA), a chronic, relapsing, hair-loss disorder, is considered to be a T cell-mediated autoimmune disease. It affects approximately 1.7% of the population, but its precise pathogenesis remains to be elucidated. Read More

    Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia.
    Expert Opin Investig Drugs 2017 Apr 16;26(4):515-522. Epub 2017 Mar 16.
    b Department of Dermatology and Cutaneous Surgery , University of Miami, Miller School of Medicine , Miami , FL , USA.
    Introduction: Alopecia is a common condition observed among people of all ages. It is a disorder that can involve only the scalp as observed in androgenetic alopecia or scalp and body as in alopecia areata or patients under chemotherapy treatment. There are several treatment options with different safety and efficacy outcomes. Read More

    Alexithymia in different dermatologic patients.
    Asian J Psychiatr 2017 Feb 12;25:42-45. Epub 2016 Oct 12.
    Department of Industrial Management, University of Tehran, Tehran, Iran.
    Alexithymia is a personality trait characterized by difficulties in differentiating and describing feelings. Research indicates that alexithymia can be considered as a possible risk factor for a variety of medical conditions. The purpose of our study was to compare and assess the prevalence of alexithymia in patients with psoriasis, alopecia areata, vitiligo and acne vulgaris. Read More

    Global Skin Disease Morbidity and Mortality: An Update From the Global Burden of Disease Study 2013.
    JAMA Dermatol 2017 Mar 1. Epub 2017 Mar 1.
    Institute for Health Metrics and Evaluation, University of Washington, Seattle.
    Importance: Disability secondary to skin conditions is substantial worldwide. The Global Burden of Disease Study 2013 includes estimates of global morbidity and mortality due to skin diseases.

    Objective: To measure the burden of skin diseases worldwide. Read More

    Escalating dosimetry of UVA-1 in the treatment of alopecia areata.
    Int J Dermatol 2017 Feb 23. Epub 2017 Feb 23.
    Dermatology Department, Universidad Autonoma de Nuevo Leon, Facultad de Medicina, University Hospital, Monterrey, Mexico.
    Background: Phototherapy can be an option in unresponsive alopecia areata (AA); however, variable results have been reported with its use. We could not find literature of treatment with UVA-1 in AA. A study was designed to evaluate progressive dosimetry to determine the initial dose and its increments. Read More

    Trichotillomania: a case report with clinical and dermatoscopic differential diagnosis with alopecia areata.
    An Bras Dermatol 2017 Jan-Feb;92(1):118-120
    Department of Dermatology of the Instituto Lauro de Souza Lima (ILSL) - Bauru (SP), Brazil.
    Trichotillomania is a psychodermatologic disorder characterized by uncontrollable urge to pull one's own hair. Differential diagnoses include the most common forms of alopecia such as alopecia areata. It is usually associated with depression and obsessive-compulsive disorder. Read More

    Quality of life assessment in patients with alopecia areata and androgenetic alopecia in the People's Republic of China.
    Patient Prefer Adherence 2017 27;11:151-155. Epub 2017 Jan 27.
    Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, People's Republic of China.
    Introduction: In medical terms, alopecia is considered a relatively mild dermatological condition that nevertheless is a serious condition, but it causes major depression in many sufferers. Alopecia areata (AA) and androgenetic alopecia (AGA) are the main types of hair loss. This study assessed the quality of life (QoL) of Chinese patients with AA and AGA using the Dermatology Life Quality Index (DLQI) questionnaire. Read More

    Janus kinase inhibitors in dermatology: A systematic review.
    J Am Acad Dermatol 2017 Apr 4;76(4):745-753.e19. Epub 2017 Feb 4.
    Department of Dermatology, Hadassah - Hebrew University Medical Center, Jerusalem, Israel. Electronic address:
    Background: Janus kinase (JAK) inhibitors are emerging as a promising new treatment modality for many inflammatory conditions.

    Objective: Our aim was to systematically review the available data on the use of JAK inhibitors in cutaneous diseases.

    Methods: This is a systematic review of PubMed and ClinicalTrials. Read More

    Erythroid Differentiation Regulator 1 as a Novel Biomarker for Hair Loss Disorders.
    Int J Mol Sci 2017 Feb 3;18(2). Epub 2017 Feb 3.
    Department of Dermatology, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul 07345, Korea.
    Erythroid differentiation regulator 1 (Erdr1) is known to be involved in the inflammatory process via regulating the immune system in many cutaneous disorders, such as psoriasis and rosacea. However, the role of Erdr1 in various hair loss disorders remains unclear. The aim of this study was to investigate the putative role of Erdr1 in alopecias. Read More

    Changes of serum trace elements level in patients with alopecia areata: A meta-analysis.
    J Dermatol 2017 Feb 2. Epub 2017 Feb 2.
    Department of Dermatology and Venerology, No. 2 Hospital of Jilin University, Changchun, China.
    Abnormalities of serum trace elements are involved in the etiology and pathogenesis of alopecia areata (AA); however, the results of published studies are controversial. The purpose of the present study is to investigate the alterations of serum level of trace elements and AA using a meta-analysis approach. We searched all articles indexed in PubMed, Embase and Science Citation Index published up to 30 April 2016 concerning the association between serum level of zinc, copper, iron/ferritin, selenium or magnesium and AA. Read More

    Sequential high- and low-dose systemic corticosteroid therapy for severe childhood alopecia areata.
    J Dtsch Dermatol Ges 2017 Jan;15(1):42-47
    Division of Immunology, Allergy and Infectious Diseases (DIAID), Department of Dermatology, Medical University of Vienna, Vienna, Austria.
    Background: Given the limited number of therapeutic options, severe childhood alopecia areata (AA) poses a clinical challenge. The best and most rapid response rates can be achieved with high-dose systemic corticosteroids, however, relapse following treatment discontinuation is inevitable. Due to systemic side effects, long-term high-dose corticosteroid regimens are not feasible. Read More

    Kombinierte Hoch-/Niedrig-Dosis-Therapie mit systemischen Glukokor-tikoiden bei schweren Verlaufsformen der Alopecia areata im Kindesalter.
    J Dtsch Dermatol Ges 2017 Jan;15(1):42-48
    Abteilung für Immundermatologie und infektiöse Hautkrankheiten (DIAID), Universitätsklinik für Dermatologie, Medizinische Universität Wien.
    Hintergrund: Schwere Verlaufsformen der Alopecia areata (AA) im Kindesalter sind aufgrund limitierter Optionen therapeutisch herausfordernd. Systemische, hochdosierte Glukokortikoide weisen die schnellste Ansprechrate auf, nach dem Absetzen kommt es allerdings zu Rezidiven. Eine längerfristige Hochdosis-Anwendung ist aufgrund der zu erwartenden Nebenwirkungen nicht empfehlenswert. Read More

    JAK inhibitors in dermatology: The promise of a new drug class.
    J Am Acad Dermatol 2017 Apr 28;76(4):736-744. Epub 2017 Jan 28.
    Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address:
    New molecularly targeted therapeutics are changing dermatologic therapy. Janus kinase-signal transducer and activator of transcription (JAK-STAT) is an intracellular signaling pathway upon which many different proinflammatory signaling pathways converge. Numerous inflammatory dermatoses are driven by soluble inflammatory mediators, which rely on JAK-STAT signaling, and inhibition of this pathway using JAK inhibitors might be a useful therapeutic strategy for these diseases. Read More

    Efficacy and safety of topical calcipotriol in management of alopecia areata: A pilot study.
    Dermatol Ther 2017 Jan 30. Epub 2017 Jan 30.
    Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
    Reports have highlighted serum vitamin D deficiency and reduced 1,25-dihydroxyvitamin D(3) receptors(VDR) expression on hair follicles of alopecia areata(AA) patients. Very few studies have demonstrated efficacy of topical calcipotriol (vitamin D analogue) in AA. We intended to study the efficacy of calcipotriol lotion 0. Read More

    Incident alopecia areata and vitiligo in adult women with atopic dermatitis: Nurses' Health Study 2.
    Allergy 2017 May 6;72(5):831-834. Epub 2017 Feb 6.
    Department of Dermatology, Warren Alpert Medical School, Providence, RI, USA.
    We aimed to determine the risk of alopecia areata (AA) and vitiligo associated with atopic dermatitis (AD) in a large cohort of US women, the Nurses' Health Study 2. We used logistic regression to calculate age- and multivariate-adjusted odds ratios to determine the risk of incident AA and vitiligo associated with AD diagnosed in or before 2009. A total of 87 406 and 87 447 participants were included in the AA and vitiligo analyses, respectively. Read More

    Remarkable Improvement of Nail Changes in Alopecia Areata Universalis with 10 Months of Treatment with Tofacitinib: A Case Report.
    Case Rep Dermatol 2016 Sep-Dec;8(3):262-266. Epub 2016 Oct 4.
    Unicesumar, Maringá, Brazil.
    Alopecia areata (AA) is a chronic, autoimmune disease. The main symptom is massive hair loss, localized or diffuse, in the scalp and the whole body. However, nails may also be involved, and brittleness, fragility and pitting can be signs of nail dystrophy in AA patients. Read More

    Late-onset alopecia areata: descriptive analysis of 30 cases.
    An Bras Dermatol 2016 Nov-Dec;91(6):844-845
    Irmandade da Santa Casa de Misericórdia de São Paulo - São Paulo (SP), Brazil.
    Alopecia areata is an autoimmune disease characterized by non-scaring hair loss. The onset in over 50-year-old patients is rare and has barely been studied. Cases of this disease have been retrospectively analyzed - according to clinical forms, extension, and associated diseases - to assess alopecia areata characteristics in a group of patients whose disease onset was after the age of 50. Read More

    Seasonal leukotrichia in a German shepherd dog. A case report.
    Tierarztl Prax Ausg K Kleintiere Heimtiere 2017 Feb 17;45(1):46-51. Epub 2017 Jan 17.
    Janine Classen, Medizinische Kleintierklinik, Zentrum für klinische Kleintiermedizin, Ludwig-Maximilians-Universität München, Veterinärstraße 13, 80539 München, E-Mail:
    Leukotrichia can be caused by a variety of metabolic and inflammatory diseases. Canine alopecia areata is a rare multifactorial benign non-scarring alopecia. This case report describes a seasonally recurrent leukotrichia associated with alopecia areata in a German shepherd dog. Read More

    Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Curr Med Chem 2017 Jan 12. Epub 2017 Jan 12.
    Department of Dermatovenereology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Salata 4, 10000 Zagreb, Croatia.
    Background: Tofacitinib (formerly known as CP-690,550, CP690550, tasocitinib), a novel selective immunosuppressant, is a small molecule classified as Janus kinase inhibitor. The aim of this review article is to present updated data summary on the tofacitinib in the field of dermatology.

    Method: We undertook a structured search of bibliographic databases for peer-reviewed scientific articles, including review articles, original research articles as well as case report articles based on inclusion/exclusion criteria. Read More

    Efficacy of superficial cryotherapy on the eyebrows of patients with alopecia universalis also treated with contact immunotherapy on the scalp: a prospective, split-face comparative study.
    Int J Dermatol 2017 Feb;56(2):184-189
    Department of Dermatology and Institute of Hair and Cosmetic Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.
    Background: Few treatment modalities are available for treating alopecia areata (AA) of the eyebrow. Due to the anatomical proximity of the eyebrows to the eyes, safety issues and side effects should always be taken into consideration when choosing the treatment modality. This study was designed to examine the efficacy of superficial cryotherapy on patients with AA of the eyebrow. Read More

    1 OF 73